Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with a new formulation, the injectable still doesn’t match the safety of entrenched competitors.

Medical photo Age-related macular degeneration (AMD)

Allergan PLC has safety data in hand now showing that a reformulated version of abicipar pegol reduced the rate of intraocular inflammation seen in otherwise successful Phase III trials of the injectable for neovascular age-related macular degeneration (nAMD) and it plans to file the candidate for US approval by mid-2019, but analysts say the drug’s current profile does not look likely to compete well with Lucentis or Eylea.

Top-line data from the 28-week, 123-patient, open-label MAPLE study released April 2 showed an incidence of intraocular inflammation (IOI) of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D